key: cord-0745162-rwr1ovs1
authors: Bajema, Kristina L.; Dahl, Rebecca M.; Prill, Mila M.; Meites, Elissa; Rodriguez-Barradas, Maria C.; Marconi, Vincent C.; Beenhouwer, David O.; Brown, Sheldon T.; Holodniy, Mark; Lucero-Obusan, Cynthia; Rivera-Dominguez, Gilberto; Morones, Rosalba Gomez; Whitmire, Alexis; Goldin, Evan B.; Evener, Steve L.; Tremarelli, Maraia; Tong, Suxiang; Hall, Aron J.; Schrag, Stephanie J.; McMorrow, Meredith; Kobayashi, Miwako; Verani, Jennifer R.; Surie, Diya; Ahmadi-Izadi, Ghazal; Burnette, Joy; Deovic, Rijalda; Epstein, Lauren; Hartley, Amy; Morales, Elena; Tanner, Tehquin; Patel, Nina; Tunson, Ashley; Elliot, Katherine; Graham, Ilda; Lama, Diki; Pena, Ismael; Perea, Adrienne; Perez, Guerry Anabelle; Simelane, Johane; Smith, Sarah; Tallin, Gabriela; Tisi, Amelia; Lopez, Alonso Arellano; Gonzalez, Miguel Covarrubias; Lengi, Bashir; Mansouri, Dena; Tamez, Mariana Vanoye; Aryanfar, Babak; Lee-Chang, Ian; Jeong, Chan; Matolek, Anthony; Mendoza, Chad; Poteshkina, Aleksandra; Naeem, Saadia; Agrawal, Madhuri; Lopez, Jessica; Peters, Theresa; Kudryavtseva, Geliya; Cates, Jordan; Folster, Jennifer M.; Kambhampati, Anita; Kelleher, Anna; Li, Yan; Ng, Han Jia; Tao, Ying
title: Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization — Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021
date: 2021-09-17
journal: MMWR Morb Mortal Wkly Rep
DOI: 10.15585/mmwr.mm7037e3
sha: 2c452baa20f0409c581b0209a14c84cab6a6c24b
doc_id: 745162
cord_uid: rwr1ovs1

COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) have been shown to be highly protective against COVID-19-associated hospitalizations (1-3). Data are limited on the level of protection against hospitalization among disproportionately affected populations in the United States, particularly during periods in which the B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, predominates (2). U.S. veterans are older, more racially diverse, and have higher prevalences of underlying medical conditions than persons in the general U.S. population (2,4). CDC assessed the effectiveness of mRNA vaccines against COVID-19-associated hospitalization among 1,175 U.S. veterans aged ≥18 years hospitalized at five Veterans Affairs Medical Centers (VAMCs) during February 1-August 6, 2021. Among these hospitalized persons, 1,093 (93.0%) were men, the median age was 68 years, 574 (48.9%) were non-Hispanic Black (Black), 475 were non-Hispanic White (White), and 522 (44.4%) had a Charlson comorbidity index score of ≥3 (5). Overall adjusted vaccine effectiveness against COVID-19-associated hospitalization was 86.8% (95% confidence interval [CI] = 80.4%-91.1%) and was similar before (February 1-June 30) and during (July 1-August 6) SARS-CoV-2 Delta variant predominance (84.1% versus 89.3%, respectively). Vaccine effectiveness was 79.8% (95% CI = 67.7%-87.4%) among adults aged ≥65 years and 95.1% (95% CI = 89.1%-97.8%) among those aged 18-64 years. COVID-19 mRNA vaccines are highly effective in preventing COVID-19-associated hospitalization in this older, racially diverse population of predominately male U.S. veterans. Additional evaluations of vaccine effectiveness among various age groups are warranted. To prevent COVID-19-related hospitalizations, all eligible persons should receive COVID-19 vaccination.

they had COVID-19-like illness (i.e., fever, new or worsened cough or shortness of breath, loss of taste or smell, oxygen saturation on room air <94%, requirement for noninvasive ventilation or endotracheal intubation with mechanical ventilation, or chest radiograph or computed tomography pulmonary findings consistent with pneumonia) (1) and a molecular test (reverse transcription-polymerase chain reaction [RT-PCR] or isothermal nucleic acid amplification test) for SARS-CoV-2 performed within 14 days before admission or during the first 72 hours of hospitalization. The first SARS-CoV-2 test within this eligibility period was considered the qualifying test. Patients with COVID-19-like illness who received a positive SARS-CoV-2 test result were included as case-patients, and those with COVID-19-like illness with negative SARS-CoV-2 test results were included as controls.

Electronic health records were reviewed to obtain data on demographic characteristics, underlying medical conditions, presenting illness, SARS-CoV-2 test results, COVID-19 vaccination history, and clinical course during hospitalization. In the Atlanta and Houston VAMCs, COVID-19 vaccination status was further verified through a review of state immunization registries. Full vaccination was defined as receipt of both doses of an mRNA vaccine (Pfizer-BioNTech or Moderna) ≥14 days before the qualifying SARS-CoV-2 test. Participants who received only 1 dose of an mRNA COVID-19 vaccine, 2 mRNA doses with receipt of the second dose <14 days before the qualifying SARS-CoV-2 test, mixed mRNA vaccine products (i.e., a different product for each dose), or the Janssen (Johnson & Johnson) COVID-19 vaccine were excluded from the analysis. Available residual clinical respiratory specimens were collected from case-patients at all sites and sent to CDC for testing. Specimens were tested using CDC's 2019-Novel Coronavirus RT-PCR Diagnostic Panel § ; those with cycle threshold values <33 were submitted for SARS-CoV-2 whole genome sequencing (6) . In addition, results from SARS-CoV-2 whole genome sequencing conducted by VAMC laboratories on clinical specimens from Atlanta, Palo Alto, and Bronx VAMCs were also reported to CDC.

Vaccine effectiveness (1 -adjusted odds ratio [aOR] × 100) ¶ to prevent COVID-19-associated hospitalization was estimated by using multivariable logistic regression to compare the odds of full vaccination between case-patients and controls. Models were adjusted for VAMC site, admission date and age (with the use of cubic splines), sex, and race/ethnicity. Additional factors were included if they changed the aOR by ≥5% when added individually to the base model. Vaccine effectiveness was compared between subgroups using 95% confidence intervals (CIs). Analyses were conducted using SAS (version 9.4; SAS Institute). Protocols were reviewed and approved by the VAMC Research and Development Committee at each site. The activity was also reviewed by CDC and conducted consistent with applicable federal law and CDC policy.** During February 1-August 6, 2021, a total of 1,494 hospitalized U.S. veterans met inclusion criteria. After excluding 319 ineligible persons (67 with missing demographic data or vaccination date or product information, 230 who received only 1 dose of mRNA COVID-19 vaccine or 2 doses <14 days before the qualifying SARS-CoV-2 test, one who received mixed mRNA COVID-19 vaccine products, and 21 who received the Janssen COVID-19 vaccine), 388 case-patients and 787 controls were included in the analysis. Among these 1,175 patients, 1,093 (93.0%) were men, the median age was 68 years (interquartile range [IQR] = 59-75 years), 574 (48.9%) were Black, and 93 (7.9%) were Hispanic ( Table 1) . Prevalence of underlying medical conditions was high and included obesity (46.8%), diabetes (43.8%), atherosclerotic cardiovascular disease (29.2%), and chronic obstructive pulmonary disease (25.4%) ( Table 1) . Overall, 54 (13.9%) case-patients and 378 (48.0%) controls were fully vaccinated. Among fully vaccinated persons, the median interval between the second COVID-19 vaccine dose and the qualifying SARS-CoV-2 test was 83 days (IQR = 49-129). Among 171 case-patients with SARS-CoV-2 lineage determined, † † Delta became the predominant variant across all sites in July 2021 ( Figure) .

The adjusted effectiveness of full vaccination in preventing COVID-19-associated hospitalization during the entire evaluation period (February 1-August 6, 2021) was 86.8% (95% CI = 80.4%-91.1%) ( Table 2 ). The adjusted vaccine effectiveness among persons admitted to the hospital before Delta variant predominance (February 1-June 30) (84.1%; 95% CI = 74.1%-90.2%) was similar to vaccine effectiveness during Delta variant predominance (July 1-August 6) (89.3%; 95% CI = 80.1%-94.3%). The estimated vaccine effectiveness among persons aged ≥65 years (79. 

Among U.S. veterans hospitalized at five VAMCs, mRNA vaccines were 86.8% effective in preventing COVID-19-associated hospitalizations and remained highly effective during a period of Delta variant predominance. The mRNA vaccines were effective against COVID-19-associated hospitalization among all age groups, although lower effectiveness (79.8%) was observed among veterans aged ≥65 years. These findings support current evidence that COVID-19 mRNA vaccines are highly effective in preventing COVID-19-associated hospitalization (1-3) and reinforce the importance of vaccination, including among veterans, who are at high risk for COVID-19 hospitalization because they are older and have a higher prevalence of underlying medical conditions compared with persons in the general U.S. population (2, 4) .

Consistent with national trends, § § Delta became the predominant SARS-CoV-2 variant in this cohort in July 2021. Protection against COVID-19-associated hospitalization remained high despite the emergence of Delta as the predominant variant in the United States; protection was similar during periods before (February-June 2021; 84.1%) and during (July-August 2021; 89.3%) Delta variant predominance. Recent reports have shown that COVID-19 vaccine protection against SARS-CoV-2 infection is lower in areas with increasing Delta variant transmission (7, 8) ; however, protection against severe disease outcomes, including hospitalization, remains high (7, 9) .

Although the observed vaccine effectiveness in this study is similar to that reported by other studies measuring protection against COVID-19-associated hospitalization, significantly lower vaccine effectiveness among older adults has not previously been observed (1, 2, 9) . This might be a result of differences in the populations evaluated; periods of vaccine effectiveness assessment, including differences in vaccine coverage, variant circulation, and time since vaccination; and variability in unmeasured confounding. Decreased immunogenicity with increasing age has been reported after vaccination with COVID-19 mRNA vaccines (10) . Because one fourth of adults included in this evaluation were aged 

What is already known about this topic? mRNA COVID-19 vaccines are effective in preventing severe COVID-19 outcomes, including hospitalization.

What is added by this report?

During February 1-August 6, 2021, vaccine effectiveness among U.S. veterans hospitalized at five Veterans Affairs Medical Centers was 87%. mRNA COVID-19 vaccines remain highly effective, including during periods of widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant. Vaccine effectiveness in preventing COVID-19-related hospitalization was 80% among adults aged ≥65 years compared with 95% among adults aged 18-64 years.

What are the implications for public health practice?

To protect against COVID-19-related hospitalization, all eligible persons should receive COVID-19 vaccination. Additional studies are needed to understand differences in COVID-19 vaccine effectiveness across age groups.

≥75 years, age-related differences in immunogenicity might have significantly contributed to lower estimated effectiveness in older persons. Additional evaluations of vaccine effectiveness across age groups, including the relationship between age and duration of protection, are warranted.

The findings in this report are subject to at least four limitations. First, although the five VAMCs included in this assessment were in diverse geographic locations, they are not representative of the entire veteran population or the general U.S. population. Second, despite the inclusion of 1,175 participants, the statistical power was insufficient to detect potential differences in vaccine effectiveness among all subgroups. Third, vaccine effectiveness estimates might be confounded by certain unmeasured behaviors, including mask use or time spent in congregate settings. Finally, the number of veterans in this sample who received the Janssen COVID-19 vaccine was too small to assess the effectiveness of this vaccine in preventing COVID-19-associated hospitalization.

These findings show that the COVID-19 mRNA vaccines remain highly effective for preventing COVID-19-associated hospitalization in this older, racially diverse population of predominantly male U.S. veterans, including during periods of widespread circulation of the SARS-CoV-2 Delta variant. However, vaccine effectiveness was lower among veterans aged ≥65 years than among those aged 18-64 years. Additional evaluations, particularly among older adults with high prevalences of underlying conditions, are important to assess vaccine effectiveness in these populations. COVID-19 vaccination of all eligible persons is essential to prevent COVID-19associated hospitalizations.

Diagnostics Testing Laboratories, CDC COVID-19 Response Team. Corresponding author: Kristina Bajema, media@cdc.gov

Department of Global Health

Public Health Surveillance and Research, Department of Veterans Affairs

Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States

Coverage and effectiveness of mRNA COVID-19 vaccines among veterans. medRxiv

BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting

COVID-19-related hospitalization rates and severe outcomes among veterans from 5

Veterans Affairs Medical Centers: hospital-based surveillance study

Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index

Rapid, sensitive, full-genome sequencing of severe acute respiratory syndrome coronavirus 2

New COVID-19 cases and hospitalizations among adults, by vaccination status

Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant-National Healthcare Safety Network

Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults-United States

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2